Elton Jeffrey North, BS, MS, PhD

Department

Pharmacy Sciences

Position

Associate Professor

General

• North E. Jeffrey, Recent advances in mycobacterial membrane protein large 3 inhibitor drug design for mycobacterial infections 2023

Publications

• American journal of pharmaceutical education
  Nystrom Kelly, A Remediation Program to Promote On-Time Graduation and Reduce Student Attrition
  87:8, p. 100416 2023
• Biophysical journal
  Yang Lixinhao, Molecular insights into anti-mycobacterial compounds targeting MmpL3
  122:3, p. 184a - 184a 2023
• Journal of medicinal chemistry
  Bhattarai Pankaj, Structural Determinants of Indole-2-carboxamides: Identification of Lead Acetamides with Pan Antimycobacterial Activity
  66:1, p. 170 - 187 2023
• Proceedings of the National Academy of Sciences of the United States of America
  Stevens Casey M., Proton transfer activity of the reconstituted Mycobacterium tuberculosis MmpL3 is modulated by substrate mimics and inhibitors
  119:30 2022
• Journal of Drug Delivery Science and Technology
  Borde Shambhavi, Formulation and characterization of ternary amorphous solid dispersions of a highly potent anti-tubercular agent and curcumin
  64 2021
• International journal of molecular sciences
  Sethiya Jigar P., MmpL3 inhibition
  21:17, p. 1 - 25 2020
• AAPS PharmSciTech
  Deodhar S., Development and In Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma
  21:6 2020
• ACS Infectious Diseases
  Li Wei, Direct Inhibition of MmpL3 by Novel Antitubercular Compounds
  5:6, p. 1001 - 1012 2019
• AAPS PharmSciTech
  Gumireddy Ashwini, Preparation, Characterization, and In vitro Evaluation of Curcumin- and Resveratrol-Loaded Solid Lipid Nanoparticles
  20:4 2019
• Frontiers in Microbiology
  Li Wei, MmpL3 as a target for the treatment of drug-resistant nontuberculous mycobacterial infections
  9:JUL 2018
• Bioorganic and Medicinal Chemistry
  Franz Nicholas D., Design, Synthesis and Evaluation of Indole-2-Carboxamides with Pan Anti-Mycobacterial Activity
  25:14, p. 3746 - 3755 2017
• Antimicrobial Agents and Chemotherapy
  Li W., Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds in Vitro
  61:4 2017
• Antimicrobial agents and chemotherapy
  Li Wei, Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3
  60:9, p. 5198 - 5207 2016
• Assay and Drug Development Technologies
  Farah Shrouq I., Opportunities and Challenges for Natural Products as Novel Antituberculosis Agents
  14:1, p. 29 - 38 2016
• ACS Infectious Diseases
  Grzegorzewicz Anna E., Covalent Modification of the Mycobacterium tuberculosis FAS-II Dehydratase by Isoxyl and Thiacetazone
  1:2, p. 91 - 97 2016
• Antimicrobial agents and chemotherapy
  Li Wei, Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis
  58:11, p. 6413 - 6423 2014
• Antimicrobial agents and chemotherapy
  Gavrish Ekaterina, In vitro and in vivo activities of hpi1, a selective antimicrobial against helicobacter pylori
  58:6, p. 3255 - 3260 2014
• Antimicrobial agents and chemotherapy
  Fleck Laura E., A screen for and validation of prodrug antimicrobials
  58:3, p. 1410 - 1419 2014
• Current Pharmaceutical Design
  Jeffrey North E., New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics
  20:27, p. 4357 - 4378 2014
• Antimicrobial agents and chemotherapy
  LaFleur Michael D., Potentiation of azole antifungals by 2-adamantanamine
  57:8, p. 3585 - 3592 2013
• Bioorganic and Medicinal Chemistry
  North E. Jeffrey, Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3- heteroaryl ureas with improved in vitro pharmacokinetic properties
  21:9, p. 2587 - 2599 2013
• Bioorganic and Medicinal Chemistry
  Scherman Michael S., Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability
  20:10, p. 3255 - 3262 2012
• Nature Chemical Biology
  Grzegorzewicz Anna E., Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane
  8:4, p. 334 - 341 2012
• Bioorganic and Medicinal Chemistry
  Brown Joshua R., The structure-activity relationship of urea derivatives as anti-tuberculosis agents
  19:18, p. 5585 - 5595 2011
• Journal of Medicinal Chemistry
  North E. Jeffrey, Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors
  53:8, p. 3095 - 3105 2010
• Bioorganic and Medicinal Chemistry
  North E. Jeffrey, Autotaxin structure-activity relationships revealed through lysophosphatidylcholine analogs
  17:9, p. 3433 - 3442 2009
• Journal of Molecular Graphics and Modelling
  Pham Truc Chi T., Molecular recognition in the sphingosine 1-phosphate receptor family
  26:8, p. 1189 - 1201 2008

Presentations

• Design and Synthesis of Novel Oxadiazole-based Antimycobacterial Agents, Morgan Harris, Wei Li, Mary Jackson, E. Jeffrey North, Midyear Clinical Meeting and Exhibition, December 6-10, 2020. 2020
• E. J. North, Assessing Student Learning, Ensuring Integrity for Multiple Pathways in a Pharmacy Program, Midwestern University, August 3, 2020. 2020
• J. Sethiya, E. J. North, DISCOVERY OF NOVEL FADD32 INHIBITOR OF MYCOBACTERIUM TUBERCULOSIS WITH IMPROVED DRUG PROPERTIES, St. Alberts Day, Creighton University 2020
• R. Scott, L. Dieckman, E. J. North, Inhibitor Characterization for a Novel Ligase (FadD32) Essential for Mycobacterial Cell Wall Biosynthesis, St. Alberts Day, Creighton University 2020
• Discovery of Novel Oxamide-based Compounds As Anti-mycobacterial Agents, Brittney Kessel, E. Jeffrey North, Midwest Student Biomedical Research Forum, University of Nebraska Medical Center, February 27, 2020. 2020
• Design and synthesis of novel sulfonamides as anti-mycobacterial agents of the mycolic acid biosynthetic pathway, Jigar P. Sethiya, E. Jeffrey North, Midwest Student Biomedical Research Forum, University of Nebraska Medical Center, February 27, 2020. 2020
• P. Agrawal, K. S. Arte, E. J. North, J. A. Tolman, Improving global tuberculosis treatment through a novel inhaled drug-device combination product, Global Health Conference Midwest 2020, February 14-15, 2020. 2020
• "Design, Synthesis and Structure Activity Relationships of Adamantyl Ureas as Anti-tuberculosis Agents, " Spring 2013 Seminar Series, University of Memphis, Department of Chemistry, 2013
• "Design, Synthesis and Biological Assessment of Adamantyl Ureas as Anti-tuberculosis Agents with Improved Selectivity and Pharmacokinetic Factors," Gordon Research Conference, New Antibacterial Discovery & Development, Lucca (Barga), Italy, April 2012. 2012
• "Design Synthesis and Biological Evaluation of Adamantyl Ureas as Anti-tuberculosis Agents," Gordon Research Conference, TB Drug Development, Lucca (Barga), Italy 2011
• "Computer-guided Discovery of Autotaxin Inhibitors," 240th American Chemical Society National Meeting, Boston, Massachusetts. 2010

Foundation/Association

• Discovery of Novel Anti-Mycobacterium tuberculosis FadD32 Inhibitors, American Association of Colleges of Pharmacy, New Investigator Award

• Discovery and Development of Therapeutics to Treat Non-tuberculous Mycobacterial Infections.
  Sponsoring organization – Creighton University
  Awarding organization – Cystic Fibrosis Foundation
  Funding status – Funded
  Percent effort – 15%
  Other faculty involved – Dr. Mary Jackson (Colorado State University).Dr. Jackson is providing microbiological testing for compounds synthesized in my lab under the Cystic Fibrosis Foundation grant.
  This project’s first funding source was the Creighton University Health Sciences Strategic Investment Fund Faculty Development Grant awarded to Dr. North from July 2017 – June 2019 ($44,202).
  Dr. Dash, Dr. Hanson and I submitted an R15 in October 2020 and has recently been scored with an impact score of 20. Likely start date for this funding mechanism is July 1, 2021.

Other

• Discovery and Development of Therapeutics to Treat Non-tuberculous Mycobacterial Infections, Creighton University, Jack and Lois Wareham Research Award

• The Identification and Optimization of Novel Anti-tuberculosis Agents, Creighton University Office of Research and Compliance Services, LB 692

Awards

• Educator of the Year Award
  Distance Class of 2021
• Recipient of the 2018 Dr. Robert Heaney Graduate Research Mentor Award
  Creighton University
• Recipient of the 2017 Scholarly Achievement Award
  Creighton University
• Recipient of the 2017 Educator of the Year Award
  Pharmacy Campus Class 2019
• Recipient of the 2015 Educator of the Year Award
  Pharmacy Distance Class 2017

Consulting

• Consultant
  Consultant for Winthrop & Weinstine Law Firm helping to understand molecular descriptions and medicinal chemistry covered in drug/drug product patents.
  Winthrop & Weinstine Law Firm
  2016 - 2017